ENXTPA:VIRPPharmaceuticals
Virbac (ENXTPA:VIRP) Stock Can Strong Margins Keep Funding Growth?
Virbac shareholders watched the stock drift over recent weeks, with the price down roughly 9% over three months, then saw a fresh verdict land as the market absorbed half year numbers. The business just printed €768m in H1 2026 revenue and an adjusted earnings before interest and tax margin of 18.8%, which is high for an animal health specialist that is still investing heavily in growth platforms.
The headline is simple: profitability held up while Virbac kept funding future products, and the...